Masimo

Masimo is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. The company provides its products to hospitals, emergency medical service providers, long-term care facilities, physician offices, veterinarians and consumers. The company's main business is Measure-through Motion and Low Perfusion? pulse oximetry monitoring, known as Masimo Signal Extraction Technology? pulse oximetry. The company's products offerings also includes noninvasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
  • TickerMASI
  • ISINUS5747951003
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
MASI MASIMO (Health Care)

MASIMO sees a downgrade to Slightly Negative on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of MASIMO (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date May 18, 2021, the closing price was USD 212.96 and its target price was estimated at USD 192.97.

MASI MASIMO (Health Care)

Masimo Corp: 1 director sold

A director at Masimo Corp sold 3,403 shares at 280.324USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

 PRESS RELEASE
MASI MASIMO (Health Care)

Company Profile for Masimo

Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been ...

Jake Strole
  • Jake Strole
MASI MASIMO (Health Care)

Morningstar | Masimo Continues to Gain Market Share, Supporting its Po...

Masimo has established itself at the forefront of algorithms and sensor technologies for patient monitoring through the development of its proprietary signal extraction technology, or SET, for use in pulse oximetry and other measurement applications. The SET platform remains leagues ahead of competing products in terms of accuracy and reliability, leading to extremely sticky customer relationships and meaningful pricing power. Masimo has developed a hybrid go-to-market model that has allowed for the proliferation of its SET and next-generation rainbow SET measurement parameters through direct ...

Jake Strole
  • Jake Strole
MASI MASIMO (Health Care)

Masimo Continues to Gain Market Share, Supporting its Positive Moat Tr...

Narrow-moat Masimo reported first-quarter financials that were in line with our expectations, although better-than-expected growth in driver placement sets the stage for continued strength throughout the remainder of the year. As we tweak our model we'll likely raise our $130 per share fair value estimate by a mid-single-digit percentage, but largely view shares as fairly valued in the market following sizable outperformance over the last year. While changes in accounting standards created some ...

MASI MASIMO (Health Care)

Masimo Corp: 1 director sold

A director at Masimo Corp sold 3,403 shares at 280.324USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

 PRESS RELEASE
MASI MASIMO (Health Care)

Company Profile for Masimo

Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been ...

 PRESS RELEASE
MASI MASIMO (Health Care)

New Study Investigates the Economic Impact and Utility of Continuous N...

MADRID--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today the findings of a recently published study in which researchers evaluated the utility of Masimo noninvasive and continuous hemoglobin (SpHb®) in reducing the number of unnecessary blood transfusions, thus reducing costs and improving quality of care.1 In the study, Dr. Ribed-Sánchez and colleagues at HM Hospitales, ETSII-Universidad Nacional de Educaíon a Distancia (UNED), and CEU San Pablo University in Spain compared the transfusion outcomes of two ...

 PRESS RELEASE
MASI MASIMO (Health Care)

Masimo SET® Pulse Oximetry Helps Form Basis of Utah Senate Resolution...

SALT LAKE CITY--(BUSINESS WIRE)-- The Utah State Legislature and Governor Gary Herbert have recently signed into law the Concurrent Resolution on Deaths From Opioid-Induced Postoperative Respiratory Depression (SCR4). The resolution urges hospitals, clinicians, and researchers to examine and identify possible links between opioids and respiratory depression following surgery and encourages doctors to prescribe home monitoring for applicable patients, which may alert caregivers to low oxygen saturation (SpO2) and changes in breathing w...

 PRESS RELEASE
MASI MASIMO (Health Care)

Masimo Reports First Quarter 2018 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 31, 2018. First Quarter 2018 Results: First quarter 2018 total revenue, including royalty and other revenue, increased to $213.0 million. Product revenues for the first quarter of 2018 increased to $204.4 million. The Company’s worldwide direct product revenue, which accounted for 87.5% of total product revenue, increased to $178.9 million in the first quarter of 2018. OEM sa...

Jake Strole
  • Jake Strole
MASI MASIMO (Health Care)

Morningstar | Masimo Continues to Gain Market Share, Supporting its Po...

Masimo has established itself at the forefront of algorithms and sensor technologies for patient monitoring through the development of its proprietary signal extraction technology, or SET, for use in pulse oximetry and other measurement applications. The SET platform remains leagues ahead of competing products in terms of accuracy and reliability, leading to extremely sticky customer relationships and meaningful pricing power. Masimo has developed a hybrid go-to-market model that has allowed for the proliferation of its SET and next-generation rainbow SET measurement parameters through direct ...

Jake Strole
  • Jake Strole
MASI MASIMO (Health Care)

Masimo Continues to Gain Market Share, Supporting its Positive Moat Tr...

Narrow-moat Masimo reported first-quarter financials that were in line with our expectations, although better-than-expected growth in driver placement sets the stage for continued strength throughout the remainder of the year. As we tweak our model we'll likely raise our $130 per share fair value estimate by a mid-single-digit percentage, but largely view shares as fairly valued in the market following sizable outperformance over the last year. While changes in accounting standards created some ...

Jake Strole
  • Jake Strole
MASI MASIMO (Health Care)

Morningstar | Masimo Beats and Raises to Start 2019; Bumping FVE

Narrow-moat Masimo reported first-quarter financials that were in line with our expectations, although better-than-expected growth in driver placement sets the stage for continued strength throughout the remainder of the year. As we tweak our model we'll likely raise our $130 per share fair value estimate by a mid-single-digit percentage, but largely view shares as fairly valued in the market following sizable outperformance over the last year. While changes in accounting standards created some revenue and gross profit comparability issues, product revenue grew approximately 13.1% in constant...

Jake Strole
  • Jake Strole
MASI MASIMO (Health Care)

Masimo Beats and Raises to Start 2019; Bumping FVE

Narrow-moat Masimo reported first-quarter financials that were in line with our expectations, although better-than-expected growth in driver placement sets the stage for continued strength throughout the remainder of the year. As we tweak our model we'll likely raise our $130 per share fair value estimate by a mid-single-digit percentage, but largely view shares as fairly valued in the market following sizable outperformance over the last year. While changes in accounting standards created some ...

Jake Strole
  • Jake Strole
MASI MASIMO (Health Care)

Morningstar | Masimo Remains on Track to Strengthen Its Economic Moat ...

Masimo has established itself at the forefront of algorithms and sensor technologies for patient monitoring through the development of its proprietary signal extraction technology, or SET, for use in pulse oximetry and other measurement applications. The SET platform remains leagues ahead of competing products in terms of accuracy and reliability, leading to extremely sticky customer relationships and meaningful pricing power. Masimo has developed a hybrid go-to-market model that has allowed for the proliferation of its SET and next-generation rainbow SET measurement parameters through direct ...

MASI MASIMO (Health Care)

MASIMO sees a downgrade to Slightly Negative on account of less fundam...

The independent financial analyst theScreener just lowered the general evaluation of MASIMO (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date May 18, 2021, the closing price was USD 212.96 and its target price was estimated at USD 192.97.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch